Pylera

Pylera is a brand name of bismuth subcitrate potassium/metronidazole/tetracycline, approved by the FDA in the following formulation(s):

PYLERA (bismuth subcitrate potassium; metronidazole; tetracycline - capsule; oral)

• 
  Manufacturer: APTALIS PHARMA US
  
  Approval date: September 28, 2006
  
  Strength(s): 140MG;125MG;125MG ^[RLD]

Has a generic version of Pylera been approved?

No. There is currently no therapeutically equivalent version of Pylera available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pylera. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Double capsule for the administration of active principles in multiple therapies
  Patent 6,350,468
  Issued: February 26, 2002
  Inventor(s): Giovanni; Sanso
  Assignee(s): Axcan Pharma Inc.
  A pharmaceutical dosage form particularly suitable for the administration of active principles in multiple therapies is disclosed. The pharmaceutical dosage form is a double capsule where in an internal capsule is placed inside an external one. Each internal and external capsule includes one or more active principles. A double capsule according to the invention is preferably used in triple or quadruple therapies against the microorganisms Helicobacter Pylori. Advantages of this pharmaceutical dosage form consist in providing a simple posology for administration of two and more active principles, allowing the active principles to activate at the right intervals of time and in the preestablished quantities, and preventing interactions between active principles. In a preferred embodiment of the invention, the pharmaceutical dosage form has an external capsule containing bismuth subcitrate and metronidazole, and an internal capsule containing tetracycline and optionally omeprazole, which is used in therapy for eradication of Helicobacter pylori.
  
  Patent expiration dates:
  
  
  • December 14, 2018
    
    ✓ 
    Patent use: PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI
  
  
  
  • December 14, 2018
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE
  
  

See also...

• Pylera Consumer Information (Drugs.com)
• Pylera Consumer Information (Wolters Kluwer)
• Pylera Consumer Information (Cerner Multum)
• Pylera Advanced Consumer Information (Micromedex)
• Bismuth Subcitrate/Metronidazole/Tetracycline Consumer Information (Wolters Kluwer)
• Bismuth subcitrate potassium, metronidazole, and tetracycline Consumer Information (Cerner Multum)
• Bismuth subcitrate, metronidazole, and tetracycline Advanced Consumer Information (Micromedex)